Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Xuanyan Xu

Xuanyan Xu

Sr. Marketing Manager, Life Sciences Audience at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.

Posts by Xuanyan Xu

FDA Speeds Up Generic Approval Process

Posted on August 30th, 2017 in Pharmacovigilance

Healthcare has been in the spotlight for much of the year so far, as Congress has wrestled with the difficult question of how to make it both better and more affordable.

(more…)

Building a balanced search formula for pharmacovigilance and literature monitoring

Posted on March 21st, 2017 in Pharmacovigilance

Adverse drug reactions are an important risk for patient safety and have significant impact on the costs of health systems. A rise in number of diseases has consequently led to a rise in number of drug consumption, which has also brought about an increase in the number of adverse drug events and drug toxicity cases. (more…)

Debates on Pharmacovigilance – What’s new and trending

Posted on March 2nd, 2017 in Pharmacovigilance

Fleming’s Pharmacovigilance & Risk Management Strategies Forum is always an excellently organized event, attended by industry leaders, policy makers and legislators. (more…)

5 Most popular Pharmacovigilance blog posts of 2016

Posted on January 26th, 2017 in Pharmacovigilance

The most-read pharmacovigilance posts of the year really demonstrate the breadth and depth of issues that professionals in this area are dealing with. In these blogs, authors tackled subjects as varied as leadership needs, compliance metrics, the role of scientific literature in identifying adverse events (more…)

  1. 1
  2. 2
  3. 3
  4. 4